Lung Cancer · 2019 · 124 citations · 35 references
MedicineOncologyPharmacoeconomicsCancer GeneticsCost-effectiveness AnalysisMolecular OncologyCancer Genome SequencingCancer GenomicsGenome SequencingLung CancerNext-generation SequencingNext-generation Sequencing In OncologyActionable Genomic AlterationsClinical Next-generation SequencingCost-effectivenessCost-effectiveness Analysis PerspectiveNext-generation Sequencing AnalysisNext-generation Sequencing InterpretationNext-generation Sequencing ValidationNext-generation Sequencing-based Detection
35
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17